Development of Parkinson's disease biomarkers

Expert Review of Neurotherapeutics

Volumn 10, Issue 12, 2010, Pages 1811-1825

  Prakash, Kumar M ^a,b,c   Tan, Eng King ^a,b,c  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

biomarkers; genomic; motor; neurochemical; neuroimaging; non motor; Parkinson's disease

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALPHA SYNUCLEIN; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BIOLOGICAL MARKER; DJ 1 PROTEIN; DOPAMINE TRANSPORTER; GLUTATHIONE; LEVODOPA; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; PARKIN; TRACER; VESICULAR MONOAMINE TRANSPORTER 2;

AMINO TERMINAL SEQUENCE; CASE CONTROL STUDY; CEREBROSPINAL FLUID; DEMENTIA; DISEASE COURSE; DISEASE MARKER; DOPPLER ECHOGRAPHY; EYE MOVEMENT; FOLLOW UP; HUMAN; MILD COGNITIVE IMPAIRMENT; MOTOR DYSFUNCTION; NERVE DEGENERATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PROTEIN CEREBROSPINAL FLUID LEVEL; REVIEW; SLEEP DISORDER;

BIOLOGICAL MARKERS; DIAGNOSTIC IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; MYOCARDIAL PERFUSION IMAGING; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY;

EID: 78649527730     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.73     Document Type: Review

References (209)

1. Biomarkers Defnitions Working Group. Biomarkers and surrogate endpoints: preferred defnitions and conceptual framework. Clin. Pharmacol. Ther. 69(3), 89-95 (2001).
2. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 17(5), 427-442 (1967).
3. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 57(8), 1497-1499 (2001).
4. Perlmutter JS. Assessment of Parkinson disease manifestations. Curr. Protoc. Neurosci. Chapter 10: Unit 10.1 (2009).
5. Marttila RJ, Rinne UK. Disability and progression in Parkinson's disease. Acta Neurol. Scand. 56(2), 159-169 (1977).
6. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N. Engl. J. Med. 328(3), 176-183 (1993).
7. Fahn S, Oakes D, Shoulson I et al. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351(24), 2498-2508 (2004).
8. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 61(4), 561-566 (2004).
9. Hely MA, Morris JG, Reid WG, Traffcante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov. Disord. 20(2), 190-199 (2005).
10. Hely MA, Morris JG, Trafcante R, Reid WG, O'Sullivan DJ, Williamson PM. The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. J. Neurol. Neurosurg. Psychiatry 67(3), 300-307 (1999).
11. Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology 65(9), 1436-1441 (2005).
12. Sato K, Hatano T, Yamashiro K et al. Prognosis of Parkinson's disease: time to stage III, I V, V, and to motor fuctuations. Mov. Disord. 21(9), 1384-1395 (2006).
13. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch. Neurol. 58(10), 1611-1615 (2001).
14. Louis ED, Tang MX, Cote L, Alfaro B, Mejia H, Marder K. Progression of parkinsonian signs in Parkinson disease. Arch. Neurol. 56(3), 334-337 (1999).
15. Burn DJ, Rowan EN, Allan LM, Molloy S, O'Brien JT, McKeith IG. Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. J. Neurol. Neurosurg. Psychiatry 77(5), 585-589 (2006). (Pubitemid 43844579)
16. Goetz CG, Stebbins GT, Blasucci LM. Differential progression of motor impairment in levodopa-treated Parkinson's disease. Mov. Disord. 15(3), 479-484 (2000).
17. Schrag A, Dodel R, Spottke A, Bornschein B, Siebert U, Quinn NP. Rate of clinical progression in Parkinson's disease. A prospective study. Mov. Disord. 22(7), 938-945 (2007).
18. Ransmayr G, Kunig G, Neubauer M, Wagner M, Falk M. Effect of age and disease duration on parkinsonian motor scores under levodopa therapy. J. Neural. Transm. Park. Dis. Dement. Sect. 9(2-3), 177-188 (1995).
19. Ross GW, Petrovitch H, Abbott RD et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann. Neurol. 63(2), 167-173 (2008).
20. Abbott RD, Petrovitch H, White LR et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 57(3), 456-462 (2001).
21. Iranzo A, Molinuevo JL, Santamaria J et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol. 5(7), 572-577 (2006).
22. Shiba M, Bower JH, Maraganore DM et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov. Disord. 15(4), 669-677 (2000).
23. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24(2), 197-211 (2003).
24. Maetzler W, Liepelt I, Berg D. Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol. 8(12), 1158-1171 (2009).
25. Haehner A, Boesveldt S, Berendse HW et al. Prevalence of smell loss in Parkinson's disease-a multicenter study. Parkinsonism Relat. Disord. 15(7), 490-494 (2009).
26. Herting B, Schulze S, Reichmann H, Haehner A, Hummel T. A longitudinal study of olfactory function in patients with idiopathic Parkinson's disease. J. Neurol. 255(3), 367-370 (2008).
27. Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general defcit unrelated to neurologic signs, disease stage, or disease duration. Neurology 38(8), 1237-1244 (1988).
28. Kim JY, Lee WY, Chung EJ, Dhong HJ. Analysis of olfactory function and the depth of olfactory sulcus in patients with Parkinson's disease. Mov. Disord. 22(11), 1563-1566 (2007).
29. Verbaan D, Boesveldt S, van Rooden SM et al. Is olfactory impairment in Parkinson disease related to phenotypic or genotypic characteristics? Neurology 71(23), 1877-1882 (2008).
30. Gagnon JF, Postuma RB, Mazza S, Doyon J, Montplaisir J. Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases. Lancet Neurol. 5, 424-432 (2006).
31. Boeve BF, Silber MH, Saper CB et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 130, 2770-2788 (2007).
32. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 46, 388-393 (1996).
33. Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 72, 1296-1300 (2009).
34. de Lau LM, Giesbergen PC, de Rijk MC et al. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology 63(7), 1240-1244 (2004).
35. Aarsland D, Andersen K, Larsen JP et al. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 56(6), 730-736 (2001).
36. Williams-Gray CH, Foltynie T, Brayne CE et al. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 130(7), 1787-1798 (2007).
37. Locascio JJ, Corkin S, Growdon JH. Relation between clinical characteristics of Parkinson's disease and cognitive decline. J. Clin. Exp. Neuropsychol. 25(1), 94-109 (2003).
38. Muslimovic D, Post B, Speelman JD et al. Cognitive decline in Parkinson's disease: a prospective longitudinal study. J. Int. Neuropsychol. Soc. 15(3), 426-437 (2009).
39. Janvin CC, Larsen JP, Aarsland D et al. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov. Disord. 21(9), 1343-1349 (2006).
40. Muslimovic D, Post B, Speelman JD et al. Cognitive profle of patients with newly diagnosed Parkinson disease. Neurology 65(8), 1239-1245 (2005).
41. Caviness JN, Driver-Dunckley E, Connor DJ et al. Defning mild cognitive impairment in Parkinson's disease. Mov. Disord. 22(9), 1272-1277 (2007).
42. Williams-Gray CH, Evans JR, Goris A et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 132(Pt 11), 2958-2969 (2009).
43. Factor SA, Feustel PJ, Friedman JH et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 60(11), 1756-1761 (2003
44. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 43(11), 2227-2229 (1993).
45. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 45(4), 669-671 (1995).
46. Aarsland D, Larsen JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch. Neurol. 56(5), 595-601 (1999).
47. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov. Disord. 20(10), 1255-1263 (2005). (Pubitemid 41645899)
48. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol. 60(3), 387-392 (2003).
49. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov. Disord. 23(6), 837-844 (2008).
50. Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 130(7), 1787-1798 (2007).
51. Jakowec M W, Petzinger GM, Sastry S, Donaldson DM, McCormack A, Langston J W. The native form of a-synuclein is not found in the cerebrospinal fuid of patients with Parkinson's disease or normal controls. Neurosci. Lett. 253(1), 13-16 (1998).
52. Borghi R, Marchese R, Negro A et al. Full length a-synuclein is present in cerebrospinal fuid from Parkinson's disease and normal subjects. Neurosci. Lett. 287(1), 65-67 (2000).
53. El-Agnaf OM, Salem SA, Paleologou KE et al. Detection of oligomeric forms of a-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 20(3), 419-425 (2006).
54. Lee PH, Lee G, Park HJ, Bang OY, Joo IS, Huh K. The plasma a-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J. Neural. Transm. 113(10), 1435-1439 (2006).
55. Tokuda T, Salem SA, Allsop D et al. Decreased a-synuclein in cerebrospinal fuid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 349(1), 162-166 (2006).
56. Maita C, Tsuji S, Yabe I et al. Secretion of DJ-1 into the serum of patients with Parkinson's disease. Neurosci. Lett. 431(1), 86-89 (2008).
57. Waragai M, Nakai M, Wei J et al. Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease. Neurosci. Lett. 425(1), 18-22 (2007).
58. Hong Z, Shi M, Chung KA, Quinn JF et al. DJ-1 and a-synuclein in human cerebrospinal fuid as biomarkers of Parkinson's disease. Brain 133(Pt 3), 713-726 (2010).
59. Connolly J, Siderowf A, Clark CM, Mu D, Pratico D. F2 isoprostane levels in plasma and urine do not support increased lipid peroxidation in cognitively impaired Parkinson disease patients. Cogn. Behav. Neurol. 21(2), 83-86 (2008).
60. Bogdanov M, Matson WR, Wang L et al. Metabolomic profling to develop blood biomarkers for Parkinson's disease. Brain 131(2), 389-396 (2008).
61. Parkinson Study Group DATATOP Investigators. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch. Neurol. 66(12), 1460-1468 (2009).
62. Zhang J, Sokal I, Peskind ER et al. CSF multianalyte profle distinguishes Alzheimer and Parkinson diseases. Am. J. Clin. Pathol. 129(4), 526-529 (2008).
63. Snow BJ, Tooyama I, McGeer EG et al. Human positron emission tomographic 18F-dopa studies correlate with dopamine cell counts and levels. Ann. Neurol. 34(3), 324-330 (1993).
64. Pate BD, Kawamata T, Yamada T et al. Correlation of striatal fuorodopa uptake in the MPTP monkey with dopaminergic indices. Ann. Neurol. 34(3), 331-338 (1993).
65. Ribeiro MJ, Vidailhet M, Nguyen JP et al. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch. Neurol. 59(4), 580-586 (2002).
66. Brooks DJ, Salmon EP, Mathias CJ et al. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure and Parkinson's disease studied by PET. Brain 113(5), 1539-1552 (1990).
67. Vingerhoets FJG, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson's disease best refects the nigrostriatal lesion? Ann. Neurol. 41(1), 58-64 (1997).
68. Broussolle E, Dentresangle C, Landais P et al. The relation of putamen and caudate nucleus 18F-dopa uptake to motor and cognitive performances in Parkinson's disease. J. Neurol. Sci. 166(2), 141-151 (1999).
69. 18F] dopa PET fndings in early Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 59(6), 597-600 (1995).
70. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 318(14), 876-880 (1988).
71. 18F]Dopa-PET study. Brain 122(9), 1637-1650 (1999). (Pubitemid 29425668)
72. 18)F]fuorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. Brain 124(6), 1125-1130 (2001).
73. Whone AL, Moore RY, Piccini P, Brooks DJ. Plasticity of the nigropallidal pathway in Parkinson's disease. Ann. Neurol. 53(2), 206-213 (2003).
74. 123I]b-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann. Neurol. 38(4), 589-598 (1995).
75. 123I]b-CIT and SPECT. Correlation with clinical fndings and comparison with multiple system atrophy and progressive supranuclear palsy. J. Neural. Transm. 50, 9-24 (1997).
76. Pirker W. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov. Disord. 18(Suppl. 7), S43-S51 (2003).
77. Pirker W, Asenbaum S, Hauk M et al. Imaging serotonin and dopamine transporters with 123I-b-CIT SPECT: binding kinetics and effects of normal aging. J. Nucl. Med. 41(1), 36-44 (2000).
78. van Dyck CH, Seibyl JP, Malison RT et al. Age-related decline in striatal dopamine transporter binding with iodine-123-b-CITSPECT. J. Nucl. Med. 36(7), 1175-1181 (1995).
79. Liu Y, Edwards RH. The role of the vescicular transport proteins in the synaptic transmission and neural degeneration. Annu. Rev. Neurosci. 20, 125-156 (1997).
80. Lee CS, Samii A, Sossi V et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopamine nerve terminals in Parkinson's disease. Ann. Neurol. 47(4), 493-503 (2000).
81. Ouchi Y, Yoshikawa E, Sekine Y et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 57(2), 168-175 (2005).
82. Gerhard A, Pavese N, Hotton G et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis. 21(2), 404-412 (2006). (Pubitemid 43099863)
83. Eshuis SA, Jager PL, Maguire RP, Jonkman S, Dierckx RA, Leenders KL. Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls. Eur. J. Nucl. Med. Mol. Imaging 36(3), 454-462 (2009).
84. Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann. Neurol. 45(5), 577-582 (1999).
85. Piccini P, Morrish PK, Turjanski N et al. Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa PET study. Ann. Neurol. 41(2), 222-229 (1997).
86. Hilker R, Klein C, Hedrich K et al. The striatal dopaminergic defcit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans. Neurosci. Lett. 323(1), 50-54 (2002).
87. Khan NL, Scherfer C, Graham E et al. Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology 64(1), 134-136 (2005).
88. Parkinson Study Group-PROGENI Investigators. Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. Neurology 73(4), 279-286 (2009).
89. Schwingenschuh P, Ruge D, Edwards MJ et al. Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study. Mov. Disord. 25(5), 560-569 (2010).
90. Ponsen MM, Stoffers D, Wolters ECH, Booij J, Berendse HW Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 81(4), 396-399 (2010).
91. Morrish PK, Rakshi JS, Bailey DL, Sawle G, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with 18F-dopa PET. J. Neurol. Neurosurg. Psychiatry 64(3), 314-319 (1998).
92. Nurmi E, Ruottinen HM, Bergman J et al. Rate of progression in Parkinson's disease: a 18-F-fuoro-dopa PET study. Mov. Disord. 16(4), 608-615 (2001).
93. 18F] fuoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study. Mov. Disord. 21(7), 958-963 (2006).
94. 123I] p-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 57(11), 2089-2094 (2001).
95. Pirker W, Djamshidian S, Asenbaum S et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal p-CIT SPECT study. Mov. Disord. 17(1), 45-53 (2002).
96. Winogrodzka A, Bergmans P, Booij J, van Royen EA, Stoof JC, Wolters EC. [(123)I] p-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 74(3), 294-298 (2003).
97. Tang CC, Poston KL, Dhawan V, Eidelberg D. Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. J. Neurosci. 30(3), 1049-1056 (2010).
98. Nandhagopal R, Kuramoto L, Schulzer M et al. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain 132(11), 2970-2979 (2009
99. Sossi V, de la Fuente-Fernández R, Holden JE, Schulzer M, Ruth TJ, Stoessl J. Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms. J. Cereb. Blood Flow Metab. 24(8), 869-876 (2004).
100. Rascol O, Brooks DJ, Korczyn AD et al. A fve-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. (056 study group). N. Engl. J. Med. 342(20), 1484-1491 (2000).
101. Clarke CE, Guttman M. Dopamine agonist monotherapy in Parkinson's disease. Lancet 360(9347), 1767-1769 (2002).
102. Rakshi JS, Pavese N, Uema T et al. A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study. J. Neural Transm. 109(12), 1433-1443 (2002).
103. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287(13), 1653-1661 (2002).
104. Whone AL, Watts RL, Stoessl AJ et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neurol. 54(1), 93-101 (2003).
105. Fahn S, Oakes D, Shoulson I et al. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351(24), 2498-2508 (2004).
106. Gill SS, Patel NK, Hotton GR et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9(5), 589-595 (2003).
107. Brundin P, Pogarell O, Hagell P et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 123(7), 1380-1390 (2000).
108. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology 51(Suppl. 2), S2-S9 (1998).
109. Moore RY, Whone AL, Brooks DJ. Extrastriatal monoamine neuron function in Parkinson's disease: an 18F-dopa PET study. Neurobiol. Dis. 29(3), 381-390 (2008).
110. Seibyl JP, Wallace E, Smith EO et al. Whole-body biodistribution, radiation absorbed dose, and brain SPECT imaging with iodine-123-b-CIT in healthy human subjects. J. Nucl. Med. 35(5), 764-770 (1994).
111. Kim SE, Choi JY, Choe YS, Choi Y, Lee Y. Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-b-CIT SPECT. J. Nucl. Med. 44(6), 870-876 (2003).
112. Brooks DJ, Piccini P. Imaging in Parkinson's disease: the role of monoaminesin behavior. Biol. Psychiatry 59(10), 908-918 (2006).
113. Guttman M, Boileau I, Warsh J et al. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur. J. Neurol. 14(5), 523-528 (2007).
114. Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ. Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology 60(4), 601-605 (2003).
115. Remy P, Doder M, Lees AJ, Turjanski N, Brooks DJ. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128(6), 1314-1322 (2005).
116. Kuhl DE, Minoshima S, Fessler JA et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease and Parkinson's disease. Ann. Neurol. 40(3), 399-410 (1996).
117. Hilker R, Thomas AV, Klein JC et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 65(11), 1716-1722 (2005).
118. Schrag A, Good CD, Miszkiel K et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 54(3), 697-702 (2000).
119. Dexter DT, Wells FR, Agid F et al. Increased nigral iron content in postmortem parkinsonian brain. Lancet 2(8569), 1219-1220 (1987).
120. Antonini A, Leenders KL, Meier D, Oertel WH, Boesiger P, Anliker M. T2 relaxation time in patients with Parkinson's disease. Neurology 43(4), 697-700 (1993).
121. Vymazal J, Righini A, Brooks RA et al. T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. Radiology 211(2), 489-495 (1999).
122. Hutchinson M, Raff U. Structural changes of the substantia nigra in Parkinson's disease as revealed by MR imaging. Am. J. Neuroradiol. 21(4), 697-701 (2000).
123. Hu MT, White SJ, Herlihy AH, Chaudhuri KR, Hajnal JV, Brooks DJ. A comparison of (18)F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson's disease. Neurology 56(9), 1195-1200 (2001).
124. Martin WR. Quantitative estimation of regional brain iron with magnetic resonance imaging. Parkinsonism Relat. Disord. 15(Suppl. 3), S215-S218 (2009).
125. Martin WR, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 70(16), 1411-1417 (2008).
126. Ashburner J, Friston KJ. Voxel-based morphometry-the methods. NeuroImage 11(6), 805-821 (2000).
127. Burton EJ, McKeith IG, Burn DJ, Williams ED, O'Brien JT. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 127(4), 791-800 (2004).
128. Summerfeld C, Junqué C, Tolosa E et al. Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. Arch. Neurol. 62(2), 281-285 (2005).
129. Ibarretxe-Bilbao N, Ramirez-Ruiz B, Junque C et al. Differential progression of brain atrophy in Parkinson disease with and without visual hallucinations. J. Neurol. Neurosurg. Psychiatry. 81(6), 650-657 (2010).
130. Ibarretxe-Bilbao N, Tolosa E, Junque C, Marti MJ. MRI and cognitive impairment in Parkinson's disease. Mov. Disord. 24(Suppl. 2), S748-S753 (2009).
131. Beyer MK, Janvin CC, Larsen JP, Aarsland D. A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. J. Neurol. Neurosurg. Psychiatry 78(3), 254-259 (2007).
132. Feldmann A, Illes Z, Kosztolanyi P et al. Morphometric changes of gray matter in Parkinson's disease with depression: a voxel-based morphometry study. Mov. Disord. 23(1), 42-46 (2008).
133. Yoshikawa K, Nakata Y, Yamada K, Nakagawa M. Early pathological changes in the parkinsonian brain demonstrated by diffusion tensor MRI. J. Neurol. Neurosurg. Psychiatry 75(3), 481-484 (2004).
134. Chan LL, Rumpel H, Yap K et al. Case control study of diffusion tensor imaging in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 78(12), 1383-1386 (2007).
135. Scherfer C, Schocke MF, Seppi K et al. Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. Brain 129(2), 538-542 (2006).
136. Matsui H, Nishinaka K, Oda M et al. Depression in Parkinson's disease. Diffusion tensor imaging study. J. Neurol. 254(9), 1170-1173 (2007). (Pubitemid 350112338)
137. Matsui H, Nishinaka K, Oda M, Niikawa H, Kubori T, Udaka F. Dementia in Parkinson's disease: diffusion tensor imaging. Acta Neurol. Scand. 116(3), 177-181 (2007). (Pubitemid 47262765)
138. Berg D. Transcranial ultrasound as a risk marker for Parkinson's disease. Mov. Disord. 24(Suppl. 2), S677-S683 (2009).
139. Berg D, Godau J, Walter U. Transcranial sonography in movement disorders. Lancet Neurol. 7(11), 1044-1055 (2008).
140. Berg D, Merz B, Reiners K, Naumann M, Becker G. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov. Disord. 20(3), 383-385 (2005).
141. Berg D, Becker G, Zeiler B et al. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 53(5), 1026-1031 (1999).
142. Hoeppner J, Prudente-Morrissey L, Herpertz SC, Benecke R, Walter U. Substantia nigra hyperechogenicity in depressive subjects relates to motor asymmetry and impaired word fuency. Eur. Arch. Psychiatry Clin. Neurosci. 259(2), 92-97 (2009).
143. Walter U, Dressler D, Probst T et al. Transcranial brain sonography fndings in discriminating between parkinsonism and idiopathic Parkinson disease. Arch. Neurol. 64(11), 1635-1640 (2007). (Pubitemid 350106766)
144. Walter U, Dressler D, Wolters A, Probst T, Grossmann A, Benecke R. Sonographic discrimination of corticobasal degeneration vs progressive supranuclear palsy. Neurology 63(3), 504-509 (2004).
145. Stockner H, Sojer M, K KS et al. Midbrain sonography in patients with essential tremor. Mov. Disord. 22(3), 414-417 (2007).
146. Berg D, Siefker C, Ruprecht-Dorfer P, Becker G. Relationship of substantia nigra echogenicity and motor function in elderly subjects. Neurology 56(1), 13-17 (2001).
147. Courbon F, Brefel-Courbon C, Thalamas C, Alibelli MJ, Berry I, Montastruc JL. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease. Mov. Disord. 18(8), 890-897 (2003).
148. Ishibashi K, Saito Y, Murayama S et al. Validation of cardiac (123)I-MIBG scintigraphy in patients with Parkinson's disease who were diagnosed with dopamine PET. Eur. J. Nucl. Med. Mol. Imaging 37(1), 3-11 (2010).
149. Fröhlich I, Diederich NJ, Pilloy W, Vaillant M. Myocardial MIBG scintigraphy: a useful clinical tool?: a retrospective study in 50 parkinsonian patients. Neurol. Sci. 31(3), 403-406 (2010).
150. Tan EK, Skipper L. Pathogenic mutations in Parkinsons disease. Hum Mutat. 28(7), 641-653 (2007).
151. Tan EK. The role of common genetic risk variants in Parkinson disease. Clin. Genet. 72(5), 387-393 (2007).
152. Goldberg MS, Lansbury PT Jr. Is there a cause-and-effect relationship between a-synuclein fbrillization and Parkinsons disease? Nat. Cell Biol. 2(7), E1 15-E1 19 (2000).
153. Krüger R, Kuhn W, Müller T et al. Ala30Pro mutation in the gene encoding a-synuclein in Parkinsons disease. Nat. Genet. 18(2), 106-108 (1998).
154. Papadimitriou A, Veletza V, Hadjigeorgiou GM, Patrikiou A, Hirano M, Anastasopoulos I. Mutated a-synuclein gene in two Greek kindreds with familial PD: incomplete penetrance? Neurology 52(3), 651-654 (1999).
155. Polymeropoulos MH, Lavedan C, Leroy E et al. Mutation in the a-synuclein gene identifed in families with Parkinsons disease. Science 276(5321), 2045-2047 (1997).
156. Singleton AB, Farrer M, Johnson J et al a-synuclein locus triplication causes Parkinsons disease. Science 302(5646), 841 (2003).
157. Tan EK, Chai A, Teo YY et al. a-synuclein haplotypes implicated in risk of Parkinson's disease. Neurology 62(1), 128-131 (2004).
158. Xiromerisiou G, Hadjigeorgiou GM, Gourbali V et al. Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identifcation of two novel LRRK2 variants. Eur. J. Neurol. 14(1), 7-11 (2007).
159. Zarranz JJ, Alegre J, Gómez-Esteban JC et al. The new mutation, E46K, of a-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55(2), 164-173 (2004).
160. Chartier-Harlin MC, Kachergus J, Roumier C et al. a-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364(9440), 1167-1169 (2004).
161. Fuchs J, Nilsson C, Kachergus J et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 68(12), 916-922 (2007).
162. Eriksen JL, Przedborski S, Petrucelli L. Gene dosage and pathogenesis of Parkinson's disease. Trends Mol. Med. 11(3), 91-96 (2005). (Pubitemid 40348985)
163. Volles MJ, Lansbury PT Jr. Zeroing in on the pathogenic form of a-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 42(26), 7871-7878 (2003).
164. Winkler S, Hagenah J, Lincoln S et al. a-synuclein and Parkinson disease susceptibility. Neurology 69(18), 1745-1750 (2007).
165. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant a-synuclein by chaperone-mediated autophagy. Science 305(5688), 1292-1295 (2004).
166. Massey AC, Kaushik S, Sovak G, Kiffn R, Cuervo AM. Consequences of the selective blockage of chaperone-mediated autophagy. Proc. Natl Acad. Sci. USA 103(15), 5805-5810 (2006).
167. Abbas N, Lücking CB, Ricard S et al. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. Hum. Mol. Genet. 8(4), 567-574 (1999).
168. Betarbet R, Sherer TB, Greenamyre JT. Ubiquitin-proteasome system and Parkinson's diseases. Exp. Neurol. 191(Suppl. 1), S17-S27 (2005).
169. Hasegawa T, Treis A, Patenge N, Fiesel FC, Springer W, Kahle PJ. Parkin protects against tyrosinase-mediated dopamine neurotoxicity by suppressing stress-activated protein kinase pathways. J. Neurochem. 105(5), 1700-1715 (2008).
170. Kitada T, Asakawa S, Hattori N et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392(6676), 605-608 (1998). (Pubitemid 28207717)
171. van de Warrenburg BP, Lammens M, Lücking CB et al. Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 56(4), 555-557 (2001).
172. Portman AT, Giladi N, Leenders KL et al. The nigrostriatal dopaminergic system in familial early onset parkinsonism with parkin mutations. Neurology 56(12), 1759-1762 (2001).
173. Valente EM, Abou-Sleiman PM, Caputo V et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304(5674), 1158-1160 (2004).
174. Tan EK, Refai FS, Siddique M et al. Clinically reported heterozygous mutations in the PINK1 kinase domain exert a gene dosage effect. Hum. Mutat. 30(11), 1551-1557 (2009).
175. Abou-Sleiman PM, Muqit MM, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci. 7(3), 207-219 (2006).
176. Tan EK. PINK1 mutations and differential effects on mitochondrial function. Exp. Neurol. 221(1), 10-12 (2010).
177. Albanese A, Valente EM, Romito LM, Bellacchio E, Elia AE, Dallapiccola B. The PINK1 phenotype can be indistinguishable from idiopathic Parkinson disease. Neurology 64(11), 1958-1960 (2005).
178. Ephraty L, Porat O, Israeli D et al. Neuropsychiatric and cognitive features in autosomalrecessive early parkinsonism due to PINK1 mutations. Mov. Disord. 22(4), 566-569 (2007).
179. Bonifati V, Rizzu P, van Baren MJ et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299(5604), 256-259 (2003). (Pubitemid 36131051)
180. Canet-Avilés RM, Wilson MA, Miller DW et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfnic aciddriven mitochondrial localization. Proc. Natl Acad. Sci. USA 101(24), 9103-9108 (2004).
181. Zhang L, Shimoji M, Thomas B et al. Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum. Mol. Genet. 14(14), 2063-2073 (2005).
182. Zimprich A, Biskup S, Leitner P et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44(4), 601-607 (2004).
183. Kumari U, Tan EK. LRRK2 in Parkinson's disease: genetic and clinical studies from patients. FEBS J. 276(22), 6455-6463 (2009).
184. Skipper L, Shen H, Chua E, et al. Analysis of LRRK2 functional domains in nondominant Parkinson disease. Neurology 65(8), 1319-1321 (2005).
185. Healy DG, Falchi M, O'Sullivan SS et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 7(7), 583-590 (2008).
186. Gilks WP, Abou-Sleiman PM, Gandhi S et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365(9457), 415-416 (2005).
187. Lesage S, Janin S, Lohmann E et al. LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans. Arch. Neurol. 64(3), 425-430 (2007).
188. Ozelius LJ, Senthil G, Saunders-Pullman R et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 354(4), 424-425 (2006).
189. Tan EK, Zhao Y, Skipper L et al. The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. Hum. Genet. 120(6), 857-863 (2007).
190. Lesage S, Dürr A, Tazir M et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N. Engl. J. Med. 354(4), 422-423 (2006).
191. Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. 29(5), 286-293 (2006).
192. Lu Y W, Tan EK. Molecular biology changes associated with LRRK2 mutations in Parkinson's disease. J. Neurosci. Res. 86(9), 1895-1901 (2008).
193. Greggio E, Jain S, Kingsbury A et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 23(2), 329-341 (2006).
194. Ito G, Okai T, Fujino G et al. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry 46(5), 1380-1388 (2007).
195. Di Fonzo A, Wu-Chou YH, Lu CS et al. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics 7(3), 133-138 (2006).
196. Tan EK, Peng R, Wu YR et al. LRRK2 G2385R modulates age at onset in Parkinson's disease: a multi-center pooled analysis. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 150B(7), 1022-1023 (2009).
197. Ross OA, Wu YR, Lee MC et al. Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann. Neurol. 64(1), 88-92 (2008).
198. Scott WK, Nance MA, Watts RL et al. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA 286(18), 2239-2244 (2001).
199. Tobin JE, Latourelle JC, Lew MF et al. Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study. Neurology 71(1), 28-34 (2008).
200. Zabetian CP, Hutter CM, Factor SA et al. Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease. Ann. Neurol. 62(2), 137-144 (2007).
201. Healy DG, Abou-Sleiman PM, Lees AJ et al. Tau gene and Parkinson's disease: a case-control study and meta-analysis. J. Neurol. Neurosurg. Psychiatry 75(7), 962-965 (2004).
202. Edwards TL, Scott WK, Almonte C et al. Genome-wide association study confrms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann. Hum. Genet. 74(2), 97-109 (2010).
203. Mata IF, Samii A, Schneer SH et al. Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch. Neurol. 65(3), 379-382 (2008).
204. Sidransky E, Nalls MA, Aasly JO et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 361(17), 1651-1661 (2009).
205. Di Fonzo A, Dekker MC, Montagna P et al. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology 72(3), 240-245 (2009).
206. Gregory A, Westaway SK, Holm IE et al. Neurodegeneration associated with genetic defects in phospholipase A(2). Neurology 71(18), 1402-1409 (2008).
207. Tan EK, Khajavi M, Thornby JI, Nagamitsu S, Jankovic J, Ashizawa T. Variability and validity of polymorphism association studies in Parkinson's disease. Neurology 55(4), 533-538 (2000).
208. Satake W, Nakabayashi Y, Mizuta I et al. Genome-wide association study identifes common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 41(12), 1303-1307 (2009).
209. Simón-Sánchez J, Schulte C, Bras JM et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 41(12), 1308-1312 (2009).